MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Hoth Therapeutics, a clinical-stage biopharmaceutical company, has been accepted into the NVIDIA Connect Program, providing the company with access to NVIDIA’s accelerated computing and AI development resources. Hoth plans to use these tools to speed computational modeling, data processing, and target evaluation across its early-stage pipeline, which includes programs in dermatology, inflammation, and oncology. The company said the program will support both internal research and collaborations by enabling larger-scale simulations and AI-driven analysis. The connection provides Hoth Therapeutics with GPU-accelerated developer tools, SDKs and APIs as well as co-marketing for increased visibility.
The move reflects broader adoption of high-performance computing in biotech, where AI-assisted drug discovery is rapidly becoming standard. For smaller developers like Hoth, access to NVIDIA tooling through an accelerator program offers a cost-effective way to modernize computational workflows without building extensive in-house hardware capacity.
Posted by MedCloudInsider Editors on 11/24/20250 comments
Aperture Therapeutics, a preclinical biotechnology company, has announced a new development candidate targeting CD33, a receptor implicated in dysfunctional microglial activity in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The therapy is designed to restore microglial homeostasis by modulating CD33 signaling, which research shows can reduce harmful inflammatory responses and improve debris clearance in the central nervous system. The company reports that preclinical work supports CD33 as a viable path toward slowing or modifying disease progression, and the candidate will advance into IND-enabling studies.
Interest in microglia-focused therapeutics has grown as genetic studies link innate immune dysregulation to neurodegeneration. Aperture’s CD33-specific approach adds a differentiated mechanism to the pipeline. The optimization of CD33 modulators was supported by the National Institute of Neurological Disorders and Stroke (NINDS/NIH).
Posted by MedCloudInsider Editors on 11/24/20250 comments
Citius Oncology plans to integrate Verix AI into the commercial launch of LYMPHIR, its recently approved IL-2 receptor–directed fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Verix AI will support real-world patient identification, streamline specialty distribution workflows, and provide field teams with coordinated insights for clinician engagement. Citius says the platform is intended to improve speed-to-treatment in a rare cancer where diagnosis is often delayed and access pathways can be complex.
The move reflects a growing trend in oncology toward using AI to accelerate therapy adoption and improve care coordination. Verix’s focus on linking patient analytics with field operations provides a more integrated approach. For health systems, the combination of LYMPHIR and Verix AI could improve identification of eligible CTCL patients—a population often managed across dermatology and oncology clinics with inconsistent data visibility.
Posted by MedCloudInsider Editors on 11/24/20250 comments
Rapid Nexus, a medical device company, has become the first to receive FDA clearance for an advanced wound-healing gel device designed to support early-stage tissue recovery. The device, Hemastyl, uses a proprietary formulation and applicator system intended for use in emergency medicine, surgery and outpatient wound care. According to the company, Hemastyl can quickly stop bleeding while creating an environment that promotes faster healing and reduces complication risks—key needs in trauma and chronic wound settings.
The clearance arrives as demand grows for technologies that address rising rates of chronic wounds linked to diabetes, vascular diseases and aging populations. Hemastyl’s combined hemostatic and healing-support approach may appeal to emergency departments and ambulatory surgical centers seeking faster, more predictable outcomes.
Posted by MedCloudInsider Editors on 11/17/20250 comments
Lunit, an AI for cancer diagnostics provider and Labcorp, an innovative laboratory service provider, have announced a strategic collaboration to expand AI-powered digital pathology research, combining Labcorp’s large-scale tissue datasets with Lunit’s AI models for slide interpretation. The partnership will focus on improving biomarker discovery, refining diagnostic accuracy and supporting translational research in oncology. Lunit’s algorithms will be applied to Labcorp’s scanned pathology slides to analyze tumor microenvironments, quantify biomarkers and identify patterns that may guide treatment selection. The companies say the work will support both early-stage research and future clinical study design.
The move highlights increasing adoption of AI in histopathology, where digitization and high-throughput image analysis are now central to cancer research. Labcorp’s extensive specimen network may give the partnership a unique advantage in scale and diversity of training data. The collaboration aims to broaden cancer and genomic correlations through the application of AI and digital pathology.
Posted by MedCloudInsider Editors on 11/17/20250 comments
Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.
The findings mark progress for CAR-T therapies in solid tumors, a field long constrained by tumor microenvironment challenges. Leucid’s “lateral” CAR architecture—designed to improve T-cell persistence and tumor penetration—could represent a breakthrough in solid tumor immunotherapy. Full Phase II results are expected in the first half 2026.
Posted by MedCloudInsider Editors on 11/10/20250 comments
Co-Diagnostics (Co-Dx), a molecular diagnosis company, announced plans to integrate its proprietary artificial intelligence algorithms into the Co-Dx Primer AI Platform, designed to accelerate PCR diagnostics. The AI component will analyze genomic data to identify optimal primer and probe sequences, reducing design time and enhancing specificity. The integration aims to support diagnostic applications in infectious diseases, oncology and other molecular testing markets.
The move highlights the growing use of AI in molecular diagnostics. Co-Diagnostics’ proprietary integration targets low-cost, rapid test development in both clinical and field environments. The models will function together with the Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer AI.
Posted by MedCloudInsider Editors on 11/04/20250 comments
Bio-Techne, a global provider of life science tools and diagnostic products along with Nucleai, have announced an AI-powered spatial biology workflow designed to accelerate predictive biomarker discovery in melanoma research. The integrated solution uses AI and biotechnology for effective treatment options personalized to the patient's needs. Early results indicate improved accuracy in identifying biomarkers linked to patient response to immunotherapy.
The partnership highlights AI’s expanding role in oncology diagnostics. By combining imaging chemistry with machine learning, Bio-Techne and Nucleai aim to enable translational researchers to move from static tissue profiling to predictive, patient-specific biomarker discovery.
Posted by MedCloudInsider Editors on 11/04/20250 comments
AIxMed dedicated to transforming cancer diagnosis and monitoring, together with PathNet, a digital pathology laboratory, has formed a strategic partnership to deploy an AI-powered urine cytology workflow designed to enhance early detection of bladder cancer. The system integrates AIxMed’s AIxURO™ technology with PathNet’s digital pathology network, allowing for automated cytology slide review and classification. The collaboration aims to reduce diagnostic variability, improve turnaround times and support hospitals transitioning from manual to AI-augmented pathology.
The partnership reflects growing adoption of AI in clinical diagnostics. The AIxMed-PathNet alliance focuses specifically on cytology—a diagnostic area historically underserved by digital tools. AIxURO™ assists with the analysis of non-invasive urine cytology specimens to improve diagnostic accuracy of bladder cancer. The collaboration is aimed towards efficiency, enhancement and overall diagnostic improvement.
Posted by MedCloudInsider Editors on 11/04/20250 comments
Labviva, a leading AI-powered source-to-pay provider for life sciences, has launched its Smart Suppliers of the Future program to accelerate digital transformation in life sciences procurement. The initiative enables suppliers to digitalize their offerings and expand their reach through Labviva's supplier network. The move expands Labviva’s marketplace to over 15 million products from 18,000 manufacturers, representing 90 percent of life sciences suppliers across the U.S. and Europe.
Labviva’s network-driven approach, linking suppliers of all sizes through AI insights and real-time pricing, positions it as a leading “Amazon-style” marketplace for scientific materials. Its AI-driven insights allow no-touch forecasting, automated inventory replenishment and seamless regulatory compliance. The aim of the platform is a frictionless supply chain that accelerates scientific discovery and source-to-pay processes.
Posted by MedCloudInsider Editors on 10/27/20250 comments
Harvard Health Publishing (HHP), part of Harvard Medical School, has licensed its library of consumer health content to Microsoft to train Copilot, the company’s AI assistant. The data includes articles on disease prevention, nutrition and wellness, all reviewed by Harvard scientists and researchers. The goal is to enhance Copilot’s accuracy when responding to healthcare-related questions. Microsoft confirmed that it paid for the license.
The deal highlights a growing focus on using trusted medical sources to improve AI reliability. By leveraging peer-reviewed, clinically verified content, Microsoft aims to strengthen Copilot’s credibility in the sensitive domain of consumer health information. This license also makes content previously exclusive to HHP subscribers available to anyone who uses Microsoft Copilot.
Posted by MedCloudInsider Editors on 10/21/20250 comments
dQ&A focuses its research efforts on diabetes to produce a unique take on treatment plans. They have released a beta version of their AI Insights Platform, designed to give healthcare companies, researchers and policymakers faster access to data on the diabetes market.
Posted by MedCloudInsider Editors on 10/17/20250 comments